-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Parkinson's Disease Drug Details: MP-101 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DNL-788 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DNL-788 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RNS-60 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RNS-60 in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RNS-60 in Acute Ischemic Stroke Drug Details: RNS-60 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Drug Details: Fenebrutinib (GDC-0853,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Obsessive-Compulsive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Obsessive-Compulsive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Obsessive-Compulsive Disorder Drug Details: Rituximab (MabThera, Rituxan, Ristova) is...